Dyne Therapeutics director granted 57,463 stock options

Dyne Therapeutics, Inc. director Barry E. Greene received a grant of stock options covering 57,463 shares of common stock on June 22, 2026.

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. director Barry E. Greene received a grant of stock options covering 57,463 shares of common stock on June 22, 2026. The options have an exercise price of $20.87 per share and expire on June 21, 2036. The underlying shares are scheduled to vest in equal monthly installments over three years through June 22, 2029, indicating a multi-year equity compensation award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 57,463 shares

Grant/Award 1 txn

Insider Greene Barry E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	57,463	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 57,463 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029.

Key Figures

Options granted: 57,463 options Exercise price: $20.87 per share Underlying shares: 57,463 shares +3 more

6 metrics

Options granted 57,463 options Stock option grant to director Barry E. Greene on June 22, 2026

Exercise price $20.87 per share Exercise price for granted Dyne Therapeutics stock options

Underlying shares 57,463 shares Common stock underlying the option grant

Total derivative holdings after grant 57,463 options Total stock options held following this transaction

Vesting period 3 years monthly Options vest in equal monthly installments through June 22, 2029

Expiration date June 21, 2036 Expiration of Dyne Therapeutics option grant to Barry E. Greene

Key Terms

Stock option (right to buy), exercise price, vesting, Common Stock, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 20.8700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying the option are scheduled to vest over three years in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

expiration date financial

"expiration_date: 2036-06-21T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dyne Therapeutics (DYN) report in this Form 4 for Barry E. Greene?

Dyne Therapeutics reported that director Barry E. Greene received a grant of stock options for 57,463 shares. These options are a compensation award, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.

How many Dyne Therapeutics (DYN) stock options were granted to Barry E. Greene?

Barry E. Greene was granted stock options covering 57,463 shares of Dyne Therapeutics common stock. This entire amount is reflected as his total derivative holdings following the grant, showing a new equity-based compensation position established on the grant date.

What is the exercise price of Barry E. Greene’s Dyne Therapeutics (DYN) stock options?

The granted stock options have an exercise price of $20.87 per share. This means Greene can purchase Dyne Therapeutics common stock at $20.87 per share upon vesting and exercise, regardless of the market price at that time.

When do Barry E. Greene’s Dyne Therapeutics (DYN) stock options vest?

The options vest in equal monthly installments over three years through June 22, 2029. This monthly vesting schedule gradually makes portions of the 57,463 underlying shares exercisable, aligning the award with ongoing board service over that period.

What is the expiration date of Barry E. Greene’s Dyne Therapeutics (DYN) option grant?

The stock options granted to Barry E. Greene expire on June 21, 2036. After this expiration date, any unexercised options will lapse, so the economic value depends on Dyne Therapeutics’ share price before that deadline.

Does this Dyne Therapeutics (DYN) Form 4 show any open-market buying or selling by Barry E. Greene?

No, the filing shows a grant of stock options as compensation, coded as an acquisition (A). There are no open-market purchase or sale transactions reported, only the establishment of a new option position for future potential exercises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greene Barry E

(Last) (First) (Middle)

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$20.87	06/22/2026		A		57,463		(1)	06/21/2036	Common Stock	57,463	$0.00	57,463	D

Explanation of Responses:

1. The option was granted on June 22, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments through June 22, 2029.

	/s/ Ron Caponigro, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)